Replies to post #15428 on Marker Therapeutics Inc (MRKR)

[Rkmatters]

No this is one of the two studies without a checkpoint inhibitor that they are funding, under c. From their PR:

TapImmune has announced its plans to initiate, in 2016, several clinical trials with TPIV 200 vaccine including: a) a 280 patient Phase II trial in triple-negative breast cancer funded by a grant from the U.S Department of Defense (DOD) to the Mayo Clinic; b) a combination trial with a checkpoint inhibitor in ovarian cancer; and, c) at least two additional trials funded and administered by TapImmune